{"analyses":[{"ciLowerLimit":"0.774","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.165","estimateComment":"Stratified Cox Proportional Model","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.6204","paramType":"Hazard Ratio (HR)","paramValue":"0.950","statisticalComment":"Stratified Log-Rank Test","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.66","upperLimit":"61.44","value":"21.6"},{"groupId":"OG001","lowerLimit":"0.07","upperLimit":"64.53","value":"21.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"270"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Overall survival is the time from randomization until death from any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"Margetuximab 15 mg/kg administered every 21 days with physician's choice of 1 of 4 backbone chemotherapy regimens.","id":"OG000","title":"Margetuximab Plus Chemotherapy"},{"description":"Trastuzumab administered every 21 days with physician's choice of 1 of 4 backbone chemotherapy regimens.","id":"OG001","title":"Trastuzumab Plus Chemotherapy"},{"description":"Margetuximab with or without chemotherapy","id":"OG002","title":"Margetuximab Infusion Substudy"}],"paramType":"MEDIAN","populationDescription":"The OS outcome measure is calculated only for the randomized study efficacy population. The 88 participants in the sub-study were not part of the efficacy population","reportingStatus":"POSTED","timeFrame":"Throughout the study, average 21 months","title":"Overall Survival (OS) Defined as the Number of Days From Randomization to the Date of Death (From Any Cause).","type":"PRIMARY","unitOfMeasure":"months"}